ELTX Elicio Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1601485 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY22.1%
TTM EPS YoY41.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-315.3%
ROA-105.3%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets52.4%
Debt / equity0.51x
Current ratio3.43x
Interest coverage-24.46x
Cash quality & payout
Operating cash flow / net income1.03x
Accruals ratio3.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $4.89M | $6.81M | $6.76M | $5.08M | $5.04M | $7.01M | $7.78M | $10.71M |
| SG&A expense | $3.56M | $3.62M | $3.85M | $3.76M | $3.01M | $3.08M | $2.96M | $2.77M |
| Operating income | -$8.45M | -$10.43M | -$10.60M | -$8.84M | -$8.04M | -$10.09M | -$10.74M | -$13.48M |
| Interest expense | $413,000 | $410,000 | $407,000 | $337,000 | $426,000 | $194,000 | $176,000 | $234,000 |
| Pretax income | -$7.92M | — | — | -$7.72M | -$10.08M | — | — | — |
| Income tax | $55,000 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$7.98M | -$8.22M | -$11.82M | -$7.72M | -$10.08M | -$10.56M | -$11.21M | -$14.00M |
| EBITDA | -$8.45M | -$10.33M | -$10.56M | -$8.79M | -$7.95M | -$9.99M | -$10.68M | -$13.39M |
| EPS (basic) | -0.30 | -0.43 | -0.65 | — | -0.60 | -0.66 | -0.87 | — |
| EPS (diluted) | -0.30 | -0.43 | -0.65 | — | -0.60 | -0.66 | -0.87 | — |
| Weighted avg. shares (diluted) | 26.29M | 19.24M | 18.21M | — | 16.69M | 16.06M | 12.95M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $30.90M | $23.48M | $14.95M | $18.56M | $20.61M | $22.09M | $18.35M | $19.49M |
| Current assets | $34.03M | $25.48M | $16.20M | $19.31M | $21.46M | $22.60M | $20.93M | $20.69M |
| PP&E, net | $182,000 | $213,000 | $249,000 | $295,000 | $328,000 | $377,000 | $430,000 | $483,000 |
| Total assets | $39.60M | $31.33M | $22.69M | $25.86M | $28.28M | $29.53M | $28.14M | $28.18M |
| Current liabilities | $9.93M | $9.20M | $7.23M | $8.11M | $6.51M | $9.92M | $11.41M | $11.52M |
| Short-term debt | $2.48M | — | — | $0 | — | — | — | — |
| Long-term debt | $7.16M | $9.54M | $9.47M | $9.41M | $9.72M | $9.34M | — | $20.03M |
| Total debt | $9.63M | $9.54M | $9.47M | $9.41M | $9.72M | $9.34M | — | $20.03M |
| Total liabilities | $20.75M | $23.39M | $24.13M | $24.23M | $24.47M | $27.69M | $19.24M | $39.49M |
| Shareholders' equity | $18.85M | $7.94M | -$1.44M | $1.64M | $3.82M | $1.83M | $8.90M | -$11.31M |
| Net debt | -$21.27M | -$13.95M | -$5.47M | -$9.16M | -$10.89M | -$12.75M | — | $542,000 |
| Shares outstanding | 28.31M | 21.90M | 18.64M | 17.80M | 17.26M | 16.26M | 15.97M | 11.03M |
| Cash flow statement | ||||||||
| Operating cash flow | -$10.36M | -$8.16M | -$11.64M | -$6.80M | -$11.09M | -$8.95M | -$10.12M | -$8.74M |
| Capital expenditure | — | — | — | $16,000 | $0 | — | — | $45,000 |
| Free cash flow | — | — | — | -$6.81M | -$11.09M | — | — | -$8.79M |
| Investing cash flow | — | — | — | -$16,000 | $0 | $0 | $0 | -$45,000 |
| Financing cash flow | $17.79M | $16.51M | $8.03M | $4.86M | $9.57M | $11.93M | $10.33M | $227,000 |
| Depreciation & amortization | $0 | $100,000 | $46,000 | $49,000 | $100,000 | $100,000 | $53,000 | $85,000 |
| Stock-based compensation | $1.11M | $935,000 | $868,000 | $772,000 | $698,000 | $710,000 | $517,000 | $464,000 |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.